Agilent unveils Biopharma CDx services lab to accelerate precision medicine

image credit- shutterstock

Agilent Technologies Inc. announced the launch of its Biopharma CDx Services Lab (BCSL) in Carpinteria, California, following receipt of California State clinical laboratory license and Clinical Laboratory Improvement Amendments (CLIA) certificate of compliance.

The BCSL and Agilent’s assay development model will support drug development from early clinical studies through regulatory approval with efficient, flexible, and streamlined companion diagnostic development. The BCSL will also provide access to innovative technologies for biomarker assessment with novel precision therapeutics in clinical trials, as well as high-quality assays that deliver robust data. The continuous development model from feasibility through FDA approval of companion diagnostics offers significant cost and time advantages to biopharma seeking to maximize the value of their investment in companion diagnostics and precision therapeutics.

“Agilent is committed to advancing the frontiers of biopharma and clinical diagnostics. The launch of the Biopharma CDx Services Lab represents a significant milestone in the company’s mission to support the development of innovative therapeutics and precision medicine,” stated Nina Green, vice president and general manager of Agilent’s Companion Diagnostics (CDx) Division. “By providing cutting-edge technologies and high-quality assays, Agilent aims to streamline the path from early clinical studies to FDA approval, accelerating the delivery of life-changing treatments to patients.”